Google
BLRX — BIOLINERX LTD (Healthcare >> Biotechnology)
BLRX FAQ
What is BLRX's ROE?
BIOLINERX LTD reports a Return on Equity (ROE) of -53.33%.
What is BLRX's dividend yield?
BIOLINERX LTD offers a dividend yield of 0.00%.
What is BLRX's Deepscope Quality Score?
Deepscope rates BLRX's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BLRX?
Deepscope's AI Timing Score for BLRX is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BLRX belong to?
BIOLINERX LTD is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 3.23
Price
-0.13
(-3.87%)
Day Change
|
|
|---|
BLRX, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 85 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.23 |
| PBV / Sector |
0.72 / 4.63
GREAT
|
| Earning Per Share | -1.92 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.31 M
GREAT
|
| Average 1W Daily Value |
0.08 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:28 |
| Symbol | BLRX |
| Name | BIOLINERX LTD |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 4.35 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 14.96 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Modi?in Technology Park, Hevel Modi'in, Israel, 7177871
Phone: 972 8 642 9100
Website: https://www.biolinerx.com
Sector: Healthcare >> Biotechnology
Description: BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
